Results 121 to 130 of about 2,933 (228)

A Novel Dual URAT1/GLUT9 Inhibitor Reduces Hyperuricemia by Enhancing Uric Acid Excretion and Attenuating Renal Fibrosis. [PDF]

Pharmaceuticals (Basel)
Zhang H, Huang J, Yang W, Zhou W, Ding J, Li Q, Hu G.   +6 more
europepmc   +1 more source

A Single- and Multiple-Dose Study to Characterize the Pharmacokinetics and Safety of Dotinurad in Healthy Chinese Adults. [PDF]

Clin Drug Investig
Liu Y, Chen Q, Sun H, Cai C, Kawamura K, Kokan R, Nomoto M.   +6 more
europepmc   +1 more source

From Multidimensional Management to Mechanistic Insight: A Review of Interventions for Hyperuricemia. [PDF]

Int J Mol Sci
Sun Q, Yin L.
europepmc   +1 more source

Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study. [PDF]

Arthritis Res Ther
Jun JB, Lee HS, Kim SH, Lee SG, Lim DH, Kim J, Park YB, Lim MJ, Hong SJ, Choi HJ, Lee SS, Kim HA, Hwang J, Suh CH, Han S, Choe JY, Yoo WH, Song JS.   +17 more
europepmc   +1 more source

Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, may substantially reduce serum urate levels, through URAT1 inhibition, potentially without adversely affecting ABCG2 function: findings from the SWITCH SURI study. [PDF]

Front Endocrinol (Lausanne)
Osonoi T, Shirabe S, Saito M, Hosoya M, Watahiki N, Douguchi S, Ofuchi K, Katoh M.   +7 more
europepmc   +1 more source

Changes in urinary albumin levels with dotinurad oral administration in hyperuricemic patients with microalbuminuria: a post hoc analysis. [PDF]

Clin Exp Nephrol
Takahashi T, Beppu T, Hosoya T, Yokota N.   +3 more
europepmc   +1 more source

A practical approach to joint pain in primary care. [PDF]

Singapore Med J
Lim JWW, Ng IKS, Goh LH, Lau TC, Lahiri M.   +4 more
europepmc   +1 more source

Current Status of Gout Arthritis: Current Approaches to Gout Arthritis Treatment: Nanoparticles Delivery Systems Approach. [PDF]

Pharmaceutics
Herdiana Y, Wardhana YW, Kurniawansyah IS, Gozali D, Wathoni N, Sofian FF.   +5 more
europepmc   +1 more source